Genetics and Insurance in Australia

Concerns around a Self-Regulated Industry

Ainsley J. Newson, Jane Tiller, Louise A. Keogh, Margaret Otlowski, Paul Lacaze

Research output: Contribution to journalArticleOtherpeer-review

8 Citations (Scopus)

Abstract

Background: Regulating the use of genetic information in insurance is an issue of ongoing international debate. In Australia, providers of life and other mutually rated insurance products can request applicants to disclose all results from any genetic test. Insurers can then use this information to adjust premiums and make policy decisions. The Australian Financial Services Council (FSC; an industry body) developed and maintains the relevant industry standard, which was updated in late 2016. Aims/Objective: To review the 2016 FSC Standard in light of relevant research and determine the legitimacy of the Australian regulatory environment regarding use of genetic information by insurers. Results: We identified five concerns arising from the 2016 FSC Standard: (1) use of results obtained from research; (2) the requirement for an applicant to disclose whether they are "considering" a genetic test; (3) failure to account for genome sequencing and other technology developments; (4) limited evidence regarding adverse selection; and (5) the inappropriateness of industry self-regulation. Conclusion: Industry self-regulation of the use of genetic information by life insurers, combined with a lack of government oversight, is inappropriate and threatens to impede the progress of genomic medicine in Australia. At this critical time, Australia requires closer government oversight of the use of genetic information in insurance.

Original languageEnglish
Pages (from-to)247-256
Number of pages10
JournalPublic Health Genomics
Volume20
Issue number4
DOIs
Publication statusPublished - 1 Nov 2017

Keywords

  • Access to life and other insurances
  • Genetic research
  • Genetic testing
  • Genetic testing policy
  • Genetics
  • Genomics
  • Health policy
  • Life insurance
  • Policy
  • Regulation

Cite this

Newson, Ainsley J. ; Tiller, Jane ; Keogh, Louise A. ; Otlowski, Margaret ; Lacaze, Paul. / Genetics and Insurance in Australia : Concerns around a Self-Regulated Industry. In: Public Health Genomics. 2017 ; Vol. 20, No. 4. pp. 247-256.
@article{fb0cc2c431f842448dfb9640ce42dac2,
title = "Genetics and Insurance in Australia: Concerns around a Self-Regulated Industry",
abstract = "Background: Regulating the use of genetic information in insurance is an issue of ongoing international debate. In Australia, providers of life and other mutually rated insurance products can request applicants to disclose all results from any genetic test. Insurers can then use this information to adjust premiums and make policy decisions. The Australian Financial Services Council (FSC; an industry body) developed and maintains the relevant industry standard, which was updated in late 2016. Aims/Objective: To review the 2016 FSC Standard in light of relevant research and determine the legitimacy of the Australian regulatory environment regarding use of genetic information by insurers. Results: We identified five concerns arising from the 2016 FSC Standard: (1) use of results obtained from research; (2) the requirement for an applicant to disclose whether they are {"}considering{"} a genetic test; (3) failure to account for genome sequencing and other technology developments; (4) limited evidence regarding adverse selection; and (5) the inappropriateness of industry self-regulation. Conclusion: Industry self-regulation of the use of genetic information by life insurers, combined with a lack of government oversight, is inappropriate and threatens to impede the progress of genomic medicine in Australia. At this critical time, Australia requires closer government oversight of the use of genetic information in insurance.",
keywords = "Access to life and other insurances, Genetic research, Genetic testing, Genetic testing policy, Genetics, Genomics, Health policy, Life insurance, Policy, Regulation",
author = "Newson, {Ainsley J.} and Jane Tiller and Keogh, {Louise A.} and Margaret Otlowski and Paul Lacaze",
year = "2017",
month = "11",
day = "1",
doi = "10.1159/000481450",
language = "English",
volume = "20",
pages = "247--256",
journal = "Public Health Genomics",
issn = "1662-4246",
publisher = "Karger",
number = "4",

}

Genetics and Insurance in Australia : Concerns around a Self-Regulated Industry. / Newson, Ainsley J.; Tiller, Jane; Keogh, Louise A.; Otlowski, Margaret; Lacaze, Paul.

In: Public Health Genomics, Vol. 20, No. 4, 01.11.2017, p. 247-256.

Research output: Contribution to journalArticleOtherpeer-review

TY - JOUR

T1 - Genetics and Insurance in Australia

T2 - Concerns around a Self-Regulated Industry

AU - Newson, Ainsley J.

AU - Tiller, Jane

AU - Keogh, Louise A.

AU - Otlowski, Margaret

AU - Lacaze, Paul

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Background: Regulating the use of genetic information in insurance is an issue of ongoing international debate. In Australia, providers of life and other mutually rated insurance products can request applicants to disclose all results from any genetic test. Insurers can then use this information to adjust premiums and make policy decisions. The Australian Financial Services Council (FSC; an industry body) developed and maintains the relevant industry standard, which was updated in late 2016. Aims/Objective: To review the 2016 FSC Standard in light of relevant research and determine the legitimacy of the Australian regulatory environment regarding use of genetic information by insurers. Results: We identified five concerns arising from the 2016 FSC Standard: (1) use of results obtained from research; (2) the requirement for an applicant to disclose whether they are "considering" a genetic test; (3) failure to account for genome sequencing and other technology developments; (4) limited evidence regarding adverse selection; and (5) the inappropriateness of industry self-regulation. Conclusion: Industry self-regulation of the use of genetic information by life insurers, combined with a lack of government oversight, is inappropriate and threatens to impede the progress of genomic medicine in Australia. At this critical time, Australia requires closer government oversight of the use of genetic information in insurance.

AB - Background: Regulating the use of genetic information in insurance is an issue of ongoing international debate. In Australia, providers of life and other mutually rated insurance products can request applicants to disclose all results from any genetic test. Insurers can then use this information to adjust premiums and make policy decisions. The Australian Financial Services Council (FSC; an industry body) developed and maintains the relevant industry standard, which was updated in late 2016. Aims/Objective: To review the 2016 FSC Standard in light of relevant research and determine the legitimacy of the Australian regulatory environment regarding use of genetic information by insurers. Results: We identified five concerns arising from the 2016 FSC Standard: (1) use of results obtained from research; (2) the requirement for an applicant to disclose whether they are "considering" a genetic test; (3) failure to account for genome sequencing and other technology developments; (4) limited evidence regarding adverse selection; and (5) the inappropriateness of industry self-regulation. Conclusion: Industry self-regulation of the use of genetic information by life insurers, combined with a lack of government oversight, is inappropriate and threatens to impede the progress of genomic medicine in Australia. At this critical time, Australia requires closer government oversight of the use of genetic information in insurance.

KW - Access to life and other insurances

KW - Genetic research

KW - Genetic testing

KW - Genetic testing policy

KW - Genetics

KW - Genomics

KW - Health policy

KW - Life insurance

KW - Policy

KW - Regulation

UR - http://www.scopus.com/inward/record.url?scp=85032347704&partnerID=8YFLogxK

U2 - 10.1159/000481450

DO - 10.1159/000481450

M3 - Article

VL - 20

SP - 247

EP - 256

JO - Public Health Genomics

JF - Public Health Genomics

SN - 1662-4246

IS - 4

ER -